Orphanetics Pharma Entwicklungs GmbH Report issue

For profit Phase 3
Founded: Innsbruck Austria (2005)
Status: Defunct (2007)

Organization Overview

First Clinical Trial
2007
NCT00432822
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

sapropterin (kuvan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Phenylketonurias (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1